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SHORT ABSTRACT 
We investigated the characteristics of patients who underwent spontaneous conversion before 
scheduled cardioversion in the ENSURE-AF study, a prospective randomized clinical trial of 
anticoagulation in patients undergoing electrical cardioversion of non-valvular atrial fibrillation. The 
study demonstrated similar efficacy and safety of the oral factor Xa inhibitor edoxaban versus 
enoxaparin–warfarin. Spontaneous conversion occurred in 7.6% of patients, and was associated with 
a history of paroxysmal atrial fibrillation but not with thromboembolic or bleeding events. 
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Strategies for urgent restoration of sinus rhythm in patients presenting with atrial fibrillation 
(AF) include heart-rate control, immediate direct-current cardioversion, and pharmacological 
cardioversion.
1
 However, cardioversion is associated with periprocedural thromboembolic events. 
Furthermore, AF symptoms can resolve spontaneously within 24 hours in many patients with new-
onset AF.
2-4
  
Rates of spontaneous conversion range from 50%
4
 to 71%
3
 in recent-onset AF, and shorter 
duration of symptoms is a significant predictor of spontaneous conversion.
5, 6
 The ability to identify 
patients with a high probability of spontaneous conversion is important, and could be used in the 
decision to postpone cardioversion and avoid the risks associated with the procedure.  
EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion Of Atrial Fibrillation 
(ENSURE-AF) is the largest prospective randomized clinical trial of anticoagulation in patients 
undergoing electrical cardioversion of non-valvular AF; the study demonstrated similar efficacy and 
safety of the oral factor Xa inhibitor edoxaban versus enoxaparin–warfarin.
7
 We performed an ancillary 
analysis using the ENSURE-AF data to determine the incidence of spontaneous conversion. Our aim 
was, first, to compare the data from patients with spontaneous conversion to those with non-
spontaneous conversion; second, to describe the characteristics and outcomes of patients with 
spontaneous conversion; and third, to identify independent predictors of spontaneous conversion, to 
more accurately identify patients who are likely to undergo spontaneous conversion to sinus rhythm. 
 
Methods 
The design of the ENSURE-AF study (ClinicalTrials.gov, number NCT02072434) has been 
described elsewhere.
7, 8
 The study design, and the distribution of spontaneous conversion in the 2 
groups and according to use of transesophageal echocardiography (TEE), is illustrated in Figure 1. 
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Figure 1. Patient disposition.  
ECV, electrical cardioversion; ITT, intention to treat; SCV, spontaneous conversion, TEE, 
transesophageal echocardiography. 
 
 In both treatment groups, cardioversion had to be performed within 3 days of randomization 
(TEE and cardioversion could be performed on the same day). All patients were followed for safety for 
30 days after completing or discontinuing the treatment.  
Patients with spontaneous conversion in the preprocedural period (confirmed by an 
electrocardiogram recording of sinus rhythm, assessed by the investigator) needed to complete 28 
days of treatment from the day that spontaneous conversion was noted, and completed 30 days of 
follow-up.  
The primary efficacy endpoint was the composite of stroke, systemic embolic event, 
myocardial infarction, or cardiovascular mortality occurring from randomization to the end of follow-up. 
The primary safety endpoint was the composite endpoint of major and clinically relevant non-major 
bleeding from the first administration of study drug to the end of treatment.  
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The primary efficacy analysis was done in the intention-to-treat population (defined as all 
patients enrolled in the study and randomly assigned.
7, 8
 The primary safety analysis included all 
patients who took at least one dose of study drug (safety population). Efficacy and safety outcomes 
were compared between patients with spontaneous conversion and patients with non-spontaneous 
conversion.  
Continuous variables are presented as mean ± standard deviation (SD). Categorical variables 
are presented as numbers and percentages of patients in each category. Data were compared using 
one-way analysis of variance for numerical data and Fisher’s exact test for categorical data.  
Logistic regression was used to determine clinical and demographic characteristics (age, 
creatinine clearance, hemoglobin value, CHA2DS2-VASc score and its components, congestive heart 
failure, hypertension, diabetes mellitus, prior stroke or transient ischemic attack, coronary artery 
disease, edoxaban dose-reduction factor, use of TEE) and prior treatment (calcium-channel blockers, 
beta-blockers, antiarrhythmic drugs, digoxin, renin−angiotensin system blockers, cardioversion 
procedure) associated with spontaneous conversion. Odds ratios and 95% confidence intervals were 
calculated.  
Statistical analysis was performed using SAS® software (SAS Institute, Cary, NC, USA). 
 
Results 
Between 25 March 2014 and 28 October 2015, 2199 patients were enrolled and randomly 
assigned to receive edoxaban (n=1095) or enoxaparin–warfarin (n=1104). Of these patients, 167 
(7.6%) underwent spontaneous conversion before scheduled electrical cardioversion, 72 patients 
(6.6%) in the edoxaban arm and 95 (8.6%) in the enoxaparin–warfarin arm. The baseline 
characteristics of the patients with spontaneous conversion or non-spontaneous conversion are 
detailed in Table I. Mean age was 63.9 ± 10.3 years in patients with spontaneous conversion and 64.3 
± 10.6 years in patients with non-spontaneous conversion. Mean CHA2DS2-VASc scores were 2.6 ± 
1.5 and 2.6 ± 1.4, respectively. History of paroxysmal AF was more frequent in the spontaneous 
conversion group (P<.001), whereas use of beta-blockers was more frequent in the non-spontaneous 
conversion group (P=.037). The TEE group was less prevalent in the spontaneous conversion group 
(P<.001). 
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  Spontaneous 
conversion  
n = 167 
Non-spontaneous 
conversion  
n = 2032 
P* 
Age (years) 63.9 ± 10.3 64.3 ± 10.6 .66 
CHA2DS2-VASc score 2.6±1.5 2.6±1.4 .94 
Congestive heart failure, n 
(%) 
67 (40.1) 893 (43.9) 0.34 
Hypertension, n (%) 131 (78.4) 1583 (77.9) 0.87 
Age ≥75y, n (%) 25 (15.0) 334 (16.4) 0.62 
Previous stroke or transient 
ischemic attack, n (%) 
7 (4.2) 127 (6.3) .29 
Vascular intervention, n (%) 15 (9.0) 160 (7.9) 0.61 
Age 65-74y, n (%) 54 (32.3) 722 (35.5) 0.41 
Female, n (%) 76 (45.5) 680 (33.5) 0.0016 
History of paroxysmal AF (≤7 
days), n (%) 
63 (37.7) 352 (17.4) <.001 
Previous cardioversion, n (%) 36 (21.6) 559 (27.6) .096 
Persistent AF, n (%) 104 (62.3) 1673 (82.3) <.001 
Prior treatment, n (%)    
Beta-blockers 119 (71.3) 1590 (78.2) .037* 
Calcium-channel blockers 34 (20.4) 464 (22.8) .46 
Renin-angiotensin 
system blockers 
101 (60.5) 1279 (62.9) .53 
Antiarrhythmic drug 
(class I/III) 
57 (34.1) 607 (29.9) .25 
Amiodarone, n (%) 41(24.6) 498(24.5) 0.990 
Propafenone, n (%) 9(5.4) 9(5.4) 9(5.4) 
Flecainide, n (%) 5(3.0) 34(1.7) 0.214 
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Others, n (%) 3(1.8) 18(0.9) 0.245 
Digoxin 24 (14.4) 278 (13.7) .80 
Use of TEE 47 (28.1) 1136 (55.9) <.001 
Table I 
Characteristics and treatment of patients with and without spontaneous conversion  
AF, atrial fibrillation; CHA2DS2-VASc, Congestive heart failure, Hypertension, Age ≥75, Diabetes 
mellitus, and prior Stroke or transient ischemic attack or thromboembolism, Vascular disease, 
Age 65–74 years, Sex category; SD, standard deviation; TEE, transesophageal echocardiography. 
*One-way analysis of variance for numerical data and Fisher’s exact test for categorical data.  
 
Forty-seven of 1147 (4.0%) patients underwent spontaneous conversion in the TEE-guided 
group versus 120 of 1002 (11.8%) patients in the non-TEE-guided group. In a multivariable logistic 
regression analysis, history of paroxysmal AF (P<.001) was associated with spontaneous conversion, 
whereas advancing age (P=.001), baseline creatinine clearance (P=.0027), and use of TEE (P<.0001) 
were associated with a reduced likelihood of spontaneous conversion (Table II).  
 
Parameter OR (95% CI) P  
History of paroxysmal AF 3.78 (2.58, 5.55) <.0001 
TEE group (vs. non-TEE group) 0.27 (0.18, 0.40) <.0001 
Age (per year increase in age) 0.96 (0.93, 0.98) .0012 
Baseline CrCl (per unit increase in 
CrCl) 
0.99 (0.98, 1.00) .0027 
Paroxysmal AF 3.78 (2.58, 5.55) <.0001 
Table II 
Multivariable logistic regression analysis of spontaneous cardioversion 
AF, atrial fibrillation; CrCl, creatinine clearance; TEE, transesophageal echocardiography. 
 
None of the patients with spontaneous conversion had a stroke, systemic embolic event, 
myocardial infarction or cardiovascular death, or had an episode of on-treatment major or major and 
clinically relevant non-major bleeding.  
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Discussion 
ENSURE-AF is the largest prospective, multicenter, randomized study in patients with AF 
undergoing planned electrical cardioversion. In this post-hoc analysis from ENSURE-AF, 7.6% of 
patients underwent spontaneous conversion, with a higher rate among the non−TEE-guided group. 
History of paroxysmal AF was the only independent predictor of spontaneous conversion. 
Spontaneous conversion was not associated with thromboembolic or bleeding events. 
An ancillary analysis of the multicenter, prospective Assessment of Cardioversion Using 
Transesophageal Echocardiography (ACUTE) trial, in which TEE-guided treatment was compared with 
conventional anticoagulation treatment for the management of AF, reported that 167 of 1041 (16%) 
patients with AF of >2 days’ duration underwent spontaneous conversion, with twice as many of those 
who converted in the conventional versus the TEE-guided group (21% vs. 11%; P<.001).
9
 The ACUTE 
II
10
 pilot trial, which compared the safety and efficacy of enoxaparin with unfractionated heparin (and 
was interrupted prematurely because of low enrollment and event rates) reported that 7 of 76 (9.2%) 
patients in the enoxaparin group and 13 of 79 (16.5%) in the unfractionated heparin group 
experienced spontaneous conversion. Similar to our study, the rate of spontaneous conversion in the 
X-VeRT study, which compared rivaroxaban with vitamin K antagonists for cardioversion in AF in 
patients with AF of >48 hours’ or unknown duration, was 7.7%.
11
 These differences in reported rates of 
spontaneous cardioversion are likely to reflect the duration of AF, which was shorter in ACUTE. 
 Given the periprocedural risks of thromboembolism, identifying predictors of spontaneous 
conversion is important for the management of patients being considered for electrical cardioversion. 
The ongoing ACWAS trial,
12
 an investigator-initiated randomized non-inferiority trial, will compare a 
watch-and-wait approach with the standard of care cardioversion in patients with recent-onset 
symptomatic AF in the emergency department without urgent need for cardioversion.  
  
Limitations 
Despite the large size of the trial, our analysis did not consider some of the predictors of 
spontaneous conversion reported in the ACUTE trial,
3
 such as New York Heart Association class, left-
atrial size, and left-atrial spontaneous echo contrast. Stunning and functional recovery of the left 
atrium and its appendage are strongly determined by the duration of AF, and we could not assess 
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delay between occurrence of AF and spontaneous conversion, or the TEE parameters in the TEE 
group. This study was limited to patients with AF of least 48 hours’ and <12 months’ duration and may 
not be applicable to patients with a shorter or longer history of AF. 
 
Conclusions 
In this contemporary study of patients with AF planned for electrical cardioversion, 7.6% of our 
population underwent spontaneous conversion, with a higher rate among the non−TEE-guided group. 
History of paroxysmal AF was the only independent predictor of spontaneous conversion. 
Spontaneous conversion to sinus rhythm was not associated with thromboembolic or bleeding events. 
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